Published 3 days ago • loading... • Updated 3 days ago
TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease
Summary by News Medical
2 Articles
2 Articles
TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease
TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH.
TRIMTECH lands $411M Biogen deal for neurodegeneration protein degraders - European Biotechnology Magazine
Cambridge-based TRIMTECH Therapeutics has signed a research collaboration and licensing option agreement with Biogen to develop small-molecule protein degraders for neurodegenerative diseases. The deal could bring TRIMTECH up to $411 million (about €373 million), plus royalties.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last Updated100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium







